Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Pancreatic Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Pancreaticobiliary Neoplasm
Pancreatic Neoplasm

Subtype

Pancreatic Neoplasm

CI-CAN-00001356Explore in graph →

Non-malignant987 active trials8 approved drugs63 evidence items

NCIt: C3305
MeSH: D010190

Overview
Statistics
Survival
Genomics19
Variants & evidence63
Drugs32
Trials4216
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (218)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 176–200 of 218 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Somatic mutations in exocrine pancreatic tumors: association with patient survival.
· PLoS One · 2013 · PMID 23565280 · validated civic_curation pubmed
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.
· J Clin Oncol · 2009 · PMID 19273710 · validated civic_curation pubmed
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
· Oncogene · 2009 · PMID 19543324 · validated civic_curation pubmed
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
· Int J Cancer · 2007 · PMID 17131328 · validated civic_curation pubmed
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
· Cancer · 2018 · PMID 29338080 · validated civic_curation pubmed
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
· Eur J Cancer · 2018 · PMID 29223478 · validated civic_curation pubmed
Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
· JCO Precis Oncol · 2019 · PMID 35100714 · validated

Showing 176–200 of 218 publications

← Previous
1
…
7
8
9
Next →

civic_curation

Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes.

· Oncotarget · 2016 · PMID 26872370 · validated civic_curation pubmed

Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicator of poor survival.

· Pancreas · 2015 · PMID 25423555 · validated civic_curation pubmed

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.

· Mol Cancer Ther · 2011 · PMID 21135251 · validated civic_curation pubmed

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.

· Cancer Discov · 2018 · PMID 29802158 · validated civic_curation pubmed

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

· Anticancer Res · 2011 · PMID 21508395 · validated civic_curation pubmed

EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.

· J Natl Compr Canc Netw · 2017 · PMID 28874593 · validated civic_curation pubmed

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.

· Clin Cancer Res · 2019 · PMID 31068372 · validated civic_curation pubmed

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

· Cancer Discov · 2018 · PMID 29903880 · validated civic_curation pubmed

Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion.

· JCO Precis Oncol · 2022 · PMID 35005993 · validated civic_curation pubmed

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

· J Clin Oncol · 2011 · PMID 22025163 · validated civic_curation pubmed

mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.

· J Clin Oncol · 2011 · PMID 21189378 · validated civic_curation pubmed

Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer.

· Cancer Biol Ther · 2018 · PMID 27466707 · validated civic_curation pubmed

Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.

· Cold Spring Harb Mol Case Stud · 2019 · PMID 31160355 · validated civic_curation pubmed

Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature.

· J Clin Pathol · 2023 · PMID 34583947 · validated civic_curation pubmed

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

· Cancer Cell · 2016 · PMID 26725216 · validated civic_curation pubmed

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.

· Oncotarget · 2014 · PMID 25216528 · validated civic_curation pubmed

Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis.

· Genet Mol Res · 2015 · PMID 26662432 · validated civic_curation pubmed

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.

· Clin Cancer Res · 2005 · PMID 16243825 · validated civic_curation pubmed